Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target
Gislaine Curty, Jez L. Marston, Miguel de Mulder Rougvie, Fábio E. Leal, Douglas F. Nixon, Marcelo A. Soares
Abstract
In diseases where epigenetic mechanisms are changed, such as cancer, many genes show altered gene expression and inhibited genes become activated. Human endogenous retrovirus type K (HERV-K) expression is usually inhibited in normal cells from healthy adults. In tumor cells, however, HERV-K mRNA expression has been frequently documented to increase. Importantly, HERV-K-derived proteins can act as tumor-specific antigens, a class of neoantigens, and induce immune responses in different types of cancer. In this review, we describe the function of the HERV-K HML-2 subtype in carcinogenesis as biomarkers, and their potential as targets for cancer immunotherapy.